Supernus Bolsters Parkinson's Portfolio With $450M Adamas Buyout: Highlights

Supernus Pharmaceuticals Inc SUPN has agreed to acquire Adamas Pharmaceuticals Inc ADMS for $9.10 per share, or $450 million.
The deal consideration includes $8.10 per share in cash ($400 million) and two non-tradable contingent value rights (CVR) collectively worth up to $1.00 per share in cash.
As of June 30, Supernus had $855.3 million in cash, cash equivalents.
The transaction is expected to close in late Q4 of 2021 or early Q1 of 2022.
The transaction strengthens Parkinson's disease portfolio with Gocovri (amantadine), the first and only FDA-approved medicine for OFF and dyskinesia in Parkinson's disease patients receiving levodopa-based therapy.
Adamas has another product, Osmolex ER (amantadine), for Parkinson's disease and drug-induced extrapyramidal reactions.
The Companies expect potential synergies of $60 million - $80 million in year one.
The acquisition is expected to be significantly accretive in 2022.
The Companies will conduct a conference call and a live webcast today at 8:30 a.m. ET.
Price Action: ADMS stock is up 72.20% at $7.94 during the premarket session on the last check Monday. SUPN shares closed 1.68% lower at $26.37 on Friday.